OncoLens, a pioneering company in cancer treatment optimization, has successfully completed a Series B funding round, securing $16 million. The funding was co-led by BIP Capital and Cross Border Impact Ventures, with participation from existing investors Martin Ventures and SeedToB. This investment comes shortly after OncoLens was recognized on the Inc. 5000 list of the fastest-growing privately held companies in America, landing at No. 1296.

Commitment to Precision Cancer Care

Based in Atlanta, OncoLens aims to revolutionize cancer care by providing timely and precise treatment planning solutions. The company's mission is to enhance collaboration among national cancer institutes (NCIs), academic medical centers, and community-based integrated delivery networks (IDNs). Utilizing advanced artificial intelligence (AI) capabilities, OncoLens delivers clinical and workflow solutions across three main pillars: multidisciplinary collaboration, data interoperability, and AI-driven informatics.

Through its proprietary AI technologies, OncoLens enables cancer centers to extract critical insights from both structured and unstructured clinical data. This capability allows providers to identify patients who may have missed vital diagnostics or therapies in real-time. Additionally, OncoLens facilitates the coordination of next steps for these patients to ensure timely intervention and a multidisciplinary approach to care.

Mark Buffington, Managing Director and CEO of BIP Capital, expressed enthusiasm for OncoLens' growth, stating, "OncoLens' focus on not just delivering insights but usability tools such as provider-targeted alerts continues to excite us along with their already impressive growth."

International Expansion and Research Network Launch

In 2022, OncoLens expanded its services internationally, launching operations in the EMEA (Europe, Middle East, and Africa) region. This move reflects the company's commitment to addressing global cancer care disparities. To further enhance its offerings, OncoLens has established the OncoLens Research Network, collaborating closely with life science organizations and clinical development teams. This network aims to conduct cutting-edge research, including clinical trials and quality improvement initiatives, to optimize cancer treatment.

Donna Parr, Managing Partner at Cross Border Impact Ventures, highlighted the significance of OncoLens' efforts, stating, "We're excited by the growth of OncoLens' network of domestic and international customers. These cancer centers and life science companies alike are closing the current disparities in care with the help of the company's cutting-edge solutions."

The Future of Cancer Treatment Planning

Anju Mathew, CEO of OncoLens, remarked on the collaborative approach the company has adopted with its provider and life science customers. "The past few years have been a true partnership with our provider and life science customers, working closely together to ensure we deliver on the promise of the right treatment at the right time for every cancer patient," Mathew said. She emphasized the company's vision to make a significant impact on cancer care, whether for patients with rare genetic alterations or those who were overlooked for clinical trials.

The recent funding will enable OncoLens to continue enhancing its platform and expand its capabilities, further solidifying its position as a leader in cancer treatment optimization.

OncoLens’ recent funding round represents a pivotal moment for the company as it strives to enhance cancer treatment solutions through innovative technology and strategic partnerships. With its commitment to improving cancer care through AI-driven insights and a collaborative network, OncoLens is poised to make significant strides in addressing the challenges faced by cancer patients and healthcare providers alike. As the company continues to grow, it remains dedicated to its mission of ensuring timely and effective treatment for all patients, particularly those in underserved communities.